<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Phys Ther Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Phys Ther Sci</journal-id><journal-id journal-id-type="publisher-id">JPTS</journal-id><journal-title-group><journal-title>Journal of Physical Therapy Science</journal-title></journal-title-group><issn pub-type="ppub">0915-5287</issn><issn pub-type="epub">2187-5626</issn><publisher><publisher-name>The Society of Physical Therapy Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27065543</article-id><article-id pub-id-type="pmc">4793008</article-id><article-id pub-id-type="publisher-id">jpts-2015-514</article-id><article-id pub-id-type="doi">10.1589/jpts.28.547</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Angiotensin-II blockage, muscle strength, and exercise capacity in physically
independent older adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Coelho</surname><given-names>Vin&#x000ed;cius A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Probst</surname><given-names>Vanessa S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nogari</surname><given-names>Bruna M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Teixeira</surname><given-names>Denilson C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Felcar</surname><given-names>Josiane M.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Denis C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gomes</surname><given-names>Marcus Vin&#x000ed;cius M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Andraus</surname><given-names>Rodrigo A. C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fernandes</surname><given-names>Karen B. P.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><aff id="aff1"><label>1)</label> Health Sciences Research Center, University of Northern
Parana (UNOPAR), Brazil</aff><aff id="aff2"><label>2)</label> Department of Physical Education, State University of
Londrina (UEL), Brazil</aff><aff id="aff3"><label>3)</label> Doctoral Program in Health Sciences, State University of
Londrina (UEL), Brazil</aff><aff id="aff4"><label>4)</label> School of Medicine, Pontificial Catholic University of
Paran&#x000e1; (PUCPR), Brazil</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Karen B.P. Fernandes, Health Sciences Research Center, University of Northern
Parana (UNOPAR): Rua Marselha 591; Londrina, Paran&#x000e1;, Brazil. (E-mail:
<email xlink:href="karenparron@gmail.com">karenparron@gmail.com</email>)</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2016</year></pub-date><volume>28</volume><issue>2</issue><fpage>547</fpage><lpage>552</lpage><history><date date-type="received"><day>16</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>2016&#x000a9;by the Society of Physical Therapy Science. Published by IPEC
Inc.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p>[Purpose] This study aimed to assess the exercise capacity and muscle strength in elderly
people using drugs for angiotensin-II blockage. [Subjects and Methods] Four hundred and
seven older adults were recruited for this study. Data about comorbidities and medication
use were recorded and the individuals were divided into three groups: control group-
elderly people with normal exercise capacity (n=235); angiotensin-converting enzyme
inhibitor group &#x02212; individuals using angiotensin-converting enzyme inhibitors (n=140); and
angiotensin-II receptor blocker group- patients using angiotensin-II receptor blockers (n=
32). Exercise capacity was evaluated by a 6-minute walking test and muscle strength was
measured using a handgrip dynamometer. [Results] Patients from the angiotensin-converting
enzyme inhibitor group (mean: 99 &#x000b1; 12%) and the angiotensin-II receptor blocker group
(mean: 101 &#x000b1; 14%) showed higher predicted values in the 6-minute walking test than the
control group patients (mean: 96 &#x000b1; 10%). Patients from the angiotensin-converting enzyme
inhibitor group (mean: 105 &#x000b1; 19%) and the angiotensin-II receptor blocker group (mean:
105.1 &#x000b1; 18.73%) showed higher predicted values of muscle strength than control group
patients (mean: 98.15 &#x000b1; 18.77%). [Conclusion] Older adults using angiotensin-converting
enzyme inhibitors or angiotensin-II receptor blockers have better functional exercise
capacity and muscle strength.</p></abstract><kwd-group><title>Key words</title><kwd>Ageing</kwd><kwd>Muscle strength</kwd><kwd>Exercise capacity</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Ageing represents one of the biggest challenges to public health worldwide. According to
the World Health Organization (WHO), currently, there are 650 million elderly (over 60&#x02005;years
of age). Of these, nearly 66% live in developing countries and this percentage may reach 75%
in 2025<xref rid="r1" ref-type="bibr">1</xref><sup>)</sup>. This marked increase in life
expectancy increases the morbidity from chronic diseases<xref rid="r2" ref-type="bibr">2</xref><sup>)</sup>, depression<xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>, and
worsens physical performance and quality of life<xref rid="r4" ref-type="bibr">4</xref><sup>)</sup>. Besides, ageing may affect physical performance of older adults,
evoking negative impacts on their behavior and consequent changes in lifestyle, causing them
to become dependent<xref rid="r5" ref-type="bibr">5</xref><sup>)</sup>. Several studies have
reported that the loss of functional capacity in elderly people is usually related to the
presence and complexity of comorbidities<xref rid="r6" ref-type="bibr">6</xref><sup>)</sup>.
Although several mechanisms may be related to this impairment of physical function in this
population, the gradual loss of muscle mass and strength is often associated with the onset
and establishment of disabilities<xref rid="r7" ref-type="bibr">7</xref><sup>)</sup>. The
relation between angiotensin converting enzyme (ACE) gene polymorphism and differences in
physical performance phenotypes have been explored during the last few years, being
described as a positive association between polymorphism insertion/deletion (I/D) of the ACE
gene and exercise performance<xref rid="r8" ref-type="bibr">8</xref><sup>)</sup>. According
to the literature, individuals with ACE insertion (I allele) present lower ACE plasma
levels<xref rid="r9" ref-type="bibr">9</xref><sup>)</sup> and an increase in slow-twitch
rather than fast-twitch muscle fibers<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r11" ref-type="bibr">11</xref><sup>)</sup> which, in turn, confers better
cardiovascular and skeletal muscle strength after training<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r12" ref-type="bibr">12</xref><sup>)</sup> with a positive effect
in endurance sporting events<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r14" ref-type="bibr">14</xref><sup>)</sup>. There are few reports about the effectiveness of
pharmacological interventions that can prevent the decline in functional capacity in older
adults. However, a cross-sectional study in healthy elderly individuals showed a positive
correlation between the use of angiotensin-converting enzyme inhibitors (ACEIs) and skeletal
muscle mass in these hypertensive patients<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>. It was also noticed that the increase in physical performance
observed after treatment with perindopril is similar to that after a six-month training
program<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup>. In addition to ACEI,
angiotensin receptor blockers (ARBs) may also modulate the effects of angiotensin II, as
they block the angiotensin-1 (T-1) receptor, regardless of the amount of angiotensin II
circulating levels<xref rid="r17" ref-type="bibr">17</xref><sup>)</sup>.</p><p>Although some reports claim that the use of ACEIs can prevent the decline in ageing-related
muscle strength, further studies are necessary to confirm this hypothesis, especially
because many studies have evaluated this effect in patients with congestive heart failure
(CHF) only and not in the elder population in general. Thus, this study aimed to evaluate if
older adults treated with ACEIs or ARBs may have a better functional exercise capacity and
muscle strength.</p></sec><sec sec-type="methods" id="s2"><title>SUBJECTS AND METHODS</title><p>All subjects enrolled in this study agreed and signed a written formal consent. The study
was approved by the Ethics Committee of the University of Northern Parana (PP070/09). This
cross-sectional study followed the criteria established by Strobe<xref rid="r18" ref-type="bibr">18</xref><sup>)</sup>. The convenience sample consisted of older adults (age
over 60&#x02005;years), according to the recommendations of the World Health Organization (WHO) for
developing countries<xref rid="r19" ref-type="bibr">19</xref><sup>)</sup> who participated
in an interdisciplinary project-the EELO Project-Study on Ageing and Longevity. The EELO
Project is a thematic project developed at the University of Northern Parana (UNOPAR), which
aims to evaluate the socio-demographic factors and indicators of health conditions of older
adults in Londrina, a city in Northern Paran&#x000e1;, Brazil. Further information can be found at
http://www2.unopar.br/sites/eelo/. This study was developed in Londrina as the elder
population of the city represents 12% of the total population-a percentage similar to that
reported for other developed countries<xref rid="r20" ref-type="bibr">20</xref>, <xref rid="r21" ref-type="bibr">21</xref><sup>)</sup>. The total sample of the EELO project
consisted of 508 individuals, corresponding to the 43,610 citizens over 60&#x02005;years old living
in Londrina. Of those, 101 individuals did not match the inclusion criteria, and therefore
were excluded from the study. Therefore, the convenience sample of the present study
consisted of 407 physically independent elderly people capable of performing basic and
instrumental activities of daily life.</p><p>The included subjects were divided into three experimental groups (according to the
medication used): the control group (CG): physically independent elderly people with
exercise capacity and muscle strength exceeding 80% of the predicted value; the ACEI group:
patients who used ACEIs for at least six months; and the ARB group: patients who used ARBs
for at least six months. Older adults using other antihypertensive drugs that may influence
muscle strength or exercise capacity (e.g., calcium channel blockers) or individuals
performing less than 80% of the predicted value of the tests were excluded from this study.
The presence of comorbidities and medication consumption were investigated through
structured questionnaires. Questions concerning height and weight were also included in
order to determine the anthropometric characteristics. Functional exercise capacity was
measured using a 6-minute walking test (6MWT). This test was performed in accordance with
the guidelines established by the American Thoracic Society (ATS)<xref rid="r22" ref-type="bibr">22</xref><sup>)</sup> and the reference values used were those described by
Troosters<xref rid="r23" ref-type="bibr">23</xref><sup>)</sup>. Data were expressed as
walking distance (in meters) and as the percentage of the predicted value.</p><p>Blood pressure, heart rate (HR), respiratory rate, symptoms of dyspnea and fatigue as well
as oxygen saturation were measured before, immediately after, and 2 minutes after test
recovery. Two tests were performed with at least a 30-minute rest period between them. A
dynamometer was used to assess muscle strength that was calibrated according to the
methodology described by Vianna<xref rid="r24" ref-type="bibr">24</xref><sup>)</sup>. The
individuals were placed in the standing position and after hand size adjustment, the device
was held comfortably aligned with the forearm, running parallel to the longitudinal axis of
the body. The proximal inter-phalangeal joint of the hand was adjusted under the support
bar, which was then pressed between the fingers and thenar region. During handgrip, the arm
remained still with flexion of the interphalangeal and metacarpophalangeal joints only.
Considering standardization, the movement of the elbow or wrist during the act of handling
was not allowed. Handgrip strength was measured in both the hands and the best result was
considered. The values obtained were compared to the reference values described by
Mathiowetz et al<xref rid="r25" ref-type="bibr">25</xref><sup>)</sup>. Data were analyzed
using the GraphPad Prism 5.0 statistical program (GraphPad Software Inc., San Diego, CA,
USA) and the significance level was set at p&#x0003c;0.05.</p><p>The normality of data distribution was verified using the Shapiro-Wilk test. Since data
were regularly distributed, parametric tests were used and descriptive data were expressed
as mean and standard deviation.</p><p>One-way analysis of variance (ANOVA) was used to compare the groups regarding muscle
strength and functional exercise capacity.</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>No differences concerning sex (p=0.99), age (p=0.46), height (p=0.11), weight (p=0.06), and
body mass index (p=0.07) were observed among the experimental groups. Therefore, it may be
assumed that the groups were similar regarding anthropometric data; results are shown in
<xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Anthropometric data of subjects in the experimental groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Anthropometric data</th><th valign="middle" align="left" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">CG (n=235)</th><th valign="middle" align="center" rowspan="1" colspan="1">ACEIG (n=140)</th><th valign="middle" align="center" rowspan="1" colspan="1">ARBG (n=32)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender</td><td align="left" valign="middle" rowspan="1" colspan="1">M</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (34.04%)</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (34.29%)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (34.38%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">155 (65.96%)</td><td align="center" valign="middle" rowspan="1" colspan="1">92 (65.71%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (65.62%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (yrs)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">69.0 &#x000b1; 6.3</td><td align="center" valign="middle" rowspan="1" colspan="1">69.5 &#x000b1; 6.4</td><td align="center" valign="middle" rowspan="1" colspan="1">70.3 &#x000b1; 5.6 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Height (cm)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">156.8 &#x000b1; 8.6</td><td align="center" valign="middle" rowspan="1" colspan="1">157.5 &#x000b1; 10.0</td><td align="center" valign="middle" rowspan="1" colspan="1">153.8 &#x000b1; 5.8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Weight (kg)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">68.2 &#x000b1; 11.7</td><td align="center" valign="middle" rowspan="1" colspan="1">71.4 &#x000b1; 12.4</td><td align="center" valign="middle" rowspan="1" colspan="1">69.6 &#x000b1; 12.5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMI (kg/m)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">27.6 &#x000b1; 4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">28.5 &#x000b1; 3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">28.6 &#x000b1; 3.8</td></tr></tbody></table><table-wrap-foot><p>M: Male, F: Female, BMI: Body Mass Index, CG: Control Group, ACEIG: Angiotensin
Converting Enzyme Inhibitor Group, ARBG: Angiotensin-II Receptor Blockers Group. Values are expressed as mean and standard deviation (Mean &#x000b1; SD)</p></table-wrap-foot></table-wrap>. A longer walking distance performed by men from the ACEIG was observed when
compared to that from those in the CG. However, the individuals from the ARBG were similar
to individuals from the ACEIG and the CG, according to one-way ANOVA (p=0.04, <xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Comparison of the walking distance (by the 6-minute-walking test [6MWT]) and
muscle strength in men from the CG, ACEIG, ARBG</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Variables</th><th valign="top" align="center" rowspan="1" colspan="1">CG</th><th valign="top" align="center" rowspan="1" colspan="1">ACEIG</th><th valign="top" align="center" rowspan="1" colspan="1">ARBG</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">6MWT (m)</td><td align="center" valign="top" rowspan="1" colspan="1">499.9 &#x000b1; 76.4</td><td align="center" valign="top" rowspan="1" colspan="1">538.1 &#x000b1; 73.3*</td><td align="center" valign="top" rowspan="1" colspan="1">516.8 &#x000b1; 84.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Muscle strength (kgf)</td><td align="center" valign="top" rowspan="1" colspan="1">33.7 &#x000b1; 5.9</td><td align="center" valign="top" rowspan="1" colspan="1">36.9 &#x000b1; 7.1*</td><td align="center" valign="top" rowspan="1" colspan="1">32.2 &#x000b1; 5.9</td></tr></tbody></table><table-wrap-foot><p>CG: Control Group, ACEIG: Angiotensin Converting Enzyme Inhibitor Group, ARBG:
Angiotensin-II Receptor Blockers Group. *Statistically different from control group, one-way ANOVA followed by Bonferroni
test</p></table-wrap-foot></table-wrap>).</p><p>Similar data were observed concerning women (p=0.04, <xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Comparison of the walking distance (by the 6-minute-walking test [6MWT]) and
muscle strength in women from the CG, ACEIG, and ARBG</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Variables</th><th valign="top" align="center" rowspan="1" colspan="1">CG</th><th valign="top" align="center" rowspan="1" colspan="1">ACEIG</th><th valign="top" align="center" rowspan="1" colspan="1"> ARBG</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">6MWT (m)</td><td align="center" valign="top" rowspan="1" colspan="1">504.4 &#x000b1; 73.9</td><td align="center" valign="top" rowspan="1" colspan="1">529 &#x000b1; 82.2*</td><td align="center" valign="top" rowspan="1" colspan="1">525.1 &#x000b1; 62.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Muscle strength (kgf)</td><td align="center" valign="top" rowspan="1" colspan="1">23.3 &#x000b1; 4.5</td><td align="center" valign="top" rowspan="1" colspan="1">24.7 &#x000b1; 4.6*</td><td align="center" valign="top" rowspan="1" colspan="1">23.5 &#x000b1; 4.7</td></tr></tbody></table><table-wrap-foot><p>CG: Control Group, ACEIG: Angiotensin Converting Enzyme Inhibitor Group, ARBG:
Angiotensin-II Receptor Blockers Group. *Statistically different from control group, one-way ANOVA followed by Bonferroni
test</p></table-wrap-foot></table-wrap>). However, when the percentage of predicted value was considered, it was
observed that individuals from both the ACEIG and the ARBG had better performance than
individuals from the CG (<xref rid="tbl_004" ref-type="table">Table 4</xref><table-wrap id="tbl_004" orientation="portrait" position="float"><label>Table 4.</label><caption><title>Comparison of the walking distance (by the 6-minute-walking test [6MWT]) and
muscle strength in individuals from the CG, ACEIG, and ARBG</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Variables</th><th valign="top" align="center" rowspan="1" colspan="1">CG</th><th valign="top" align="center" rowspan="1" colspan="1">ACEIG</th><th valign="top" align="center" rowspan="1" colspan="1"> ARBG</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">6MWT (% predicted value)</td><td align="center" valign="top" rowspan="1" colspan="1">95.6 &#x000b1; 9.9</td><td align="center" valign="top" rowspan="1" colspan="1">99.2 &#x000b1; 12.1*</td><td align="center" valign="top" rowspan="1" colspan="1">100.9 &#x000b1; 13.6*</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Muscle strength (% predicted value)</td><td align="center" valign="top" rowspan="1" colspan="1">98.1 &#x000b1; 17.7</td><td align="center" valign="top" rowspan="1" colspan="1">104.8 &#x000b1; 18.8*</td><td align="center" valign="top" rowspan="1" colspan="1">105.1 &#x000b1; 18.7*</td></tr></tbody></table><table-wrap-foot><p>CG: Control Group, ACEIG: Angiotensin Converting Enzyme Inhibitor Group, ARBG:
Angiotensin-II Receptor Blockers Group. *Statistically different from control group, one-way ANOVA followed by Bonferroni
test</p></table-wrap-foot></table-wrap>). Regarding muscle strength, men from the ACEIG had higher values when
compared to those of men from the CG. However, the individuals from the ARBG were similar to
individuals from the ACEIG and the CG, according to one-way ANOVA (p=0.04, <xref rid="tbl_002" ref-type="table">Table 2</xref>). Similar data were observed concerning
women (p=0.04, <xref rid="tbl_003" ref-type="table">Table 3</xref>). By contrast, when the
percentage of the predicted value was considered, it was observed that individuals from both
the ACEIG and the ARBG had better performance than individuals from the CG (<xref rid="tbl_004" ref-type="table">Table 4</xref>).</p></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>In this study, we found that elder individuals who use ACEIs or ARBs have better exercise
capacity compared to those elderly who do not use this medication. This result is in
agreement with the results of the study by Onder et al.<xref rid="r26" ref-type="bibr">26</xref><sup>)</sup> who also observed a better physical performance in individuals
using ACEIs. Additionally, we also observed an increase in the muscle strength in older
adults treated with both ACEIs and ARBs, showing concordance with the results of the study
by Di Bari, et al.<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>, that describes a
rise in muscle mass in elder patients treated with ACEIs. Moreover, Sumukadas et al.<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup> reported that treatment with Perindopril
may increase exercise capacity similar to that by a six-month physical training program.
Vescovo et al.<xref rid="r27" ref-type="bibr">27</xref><sup>)</sup> reported significant
increases in maximum oxygen uptake (VO<sub>2</sub>max) and ventilatory threshold after six
months of treatment with losartan. Additionally, Corder et al.<xref rid="r28" ref-type="bibr">28</xref><sup>)</sup> observed an increase in VO<sub>2</sub>max and exercise
duration after twelve weeks of treatment with Cilazapril in individuals with CHF. On the
other hand, treatment with enalapril in patients with CHF evoked no changes in exercise
capacity and VO<sub>2</sub>max, although a significant increase in the density of skeletal
muscle fibers was observed<xref rid="r29" ref-type="bibr">29</xref><sup>)</sup>.</p><p>The exact mechanism by which pharmacological blockade of angiotensin-II influences the
physical performance is still unclear. However, several hypotheses could be postulated
according to Onder, et al<xref rid="r26" ref-type="bibr">26</xref><sup>)</sup>. Initially,
it can be assumed that the blockade of angiotensin-II could trigger metabolic and mechanical
changes in the skeletal muscle. In this context, ACEIs increase insulin sensitivity,
glycogen stockage, and glucose uptake by skeletal muscles, improving muscle metabolic
efficiency<xref rid="r30" ref-type="bibr">30</xref><sup>)</sup>. In addition, decreased
degradation of bradykinin by blocking the ACE could improve the blood flow to the skeletal
muscles through vasodilatation and an increase in capillary permeability, thus increasing
the uptake of glucose and amino acids also, contributing to a higher metabolic
efficiency<xref rid="r31" ref-type="bibr">31</xref><sup>)</sup>. Besides, ACEIs can reduce
the inflammatory response produced by angiotensin-II<xref rid="r32" ref-type="bibr">32</xref><sup>)</sup>, which increases the production of interleukin 6 (IL-6) and alpha
tumor necrosis factor (TNF&#x003b1;) in vascular smooth muscle cells<xref rid="r33" ref-type="bibr">33</xref><sup>)</sup>. This reduction in inflammatory status is also related to the
prevention of loss of muscle mass. The ACEIs may exhibit this effect since they indirectly
potentiate the action of bradykinin, which, in turn, releases nitric oxide, a potent
suppressant agent of the inflammatory response<xref rid="r34" ref-type="bibr">34</xref><sup>)</sup>.</p><p>From these results, it can be suggested that the beneficial effect observed by treatment
with ACEIs may be at least partially mediated by bradykinin, since the ACEIs limit the
degradation of bradykinin, which plays an important role in modulating endothelium relaxing
factors<xref rid="r31" ref-type="bibr">31</xref><sup>)</sup>. The reduction of bradykinin
as a result of ACE inhibition may increase the blood supply to the skeletal muscles by
causing vasodilation and increased capillary density, favoring the uptake of glucose and
amino acids, leading to a higher metabolic efficiency<xref rid="r35" ref-type="bibr">35</xref><sup>)</sup>. These data may suggest that this beneficial effect on the physical
performance is due to ACE inhibition and not only due to the pharmacological effects of
angiotensin II. As limitations of this study, it is important to analyze whether this effect
was dose or time dependent. Inflammatory biomarker levels (such as IL-6 and TNF&#x003b1;) were not
assessed in this study. Furthermore, it should be highlighted that cohort as well as
clinical randomized trials should be conducted to confirm this hypothesis.</p><p>Considering the beneficial effect of these drug types on physical performance, it can be
suggested that such drugs may contribute to a smaller decline in physical capacity related
to the ageing process. It can be concluded that older adults who use ACEIs or ARBs may have
a better functional exercise capacity and muscle strength compared to those in controls.
Thus, elderly who use this medication may present a lower decline of functional capacity
related to the ageing process.</p></sec></body><back><ack><p>The authors thank CNPQ, CAPES and Funda&#x000e7;&#x000e3;o Manoel de Barros for financial support of this
project.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>De Luca d&#x02019;Alessandro</surname><given-names>E</given-names></name><name><surname>Bonacci</surname><given-names>S</given-names></name><name><surname>Giraldi</surname><given-names>G</given-names></name></person-group>: <article-title>Aging populations: the health and quality of life of the
elderly</article-title>. <source>Clin Ter</source>, <year>2011</year>,
<volume>162</volume>: <fpage>e13</fpage>&#x02013;<lpage>e18</lpage>. <pub-id pub-id-type="pmid">21448536</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Holman</surname><given-names>H</given-names></name></person-group>: <article-title>Chronic disease&#x02014;the need for a new clinical
education</article-title>. <source>JAMA</source>, <year>2004</year>,
<volume>292</volume>: <fpage>1057</fpage>&#x02013;<lpage>1059</lpage>. <pub-id pub-id-type="pmid">15339897</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Jee</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>YB</given-names></name></person-group>: <article-title>Factors influencing depression among elderly patients in
geriatric patients</article-title>. <source>J Phys Ther Sci</source>, <year>2013</year>,
<volume>25</volume>: <fpage>1445</fpage>&#x02013;<lpage>1449</lpage>. <pub-id pub-id-type="pmid">24396207</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Nakano</surname><given-names>MM</given-names></name><name><surname>Otonari</surname><given-names>TS</given-names></name><name><surname>Takara</surname><given-names>KS</given-names></name><etal>et al.</etal></person-group>: <article-title>Physical performance, balance, mobility, and muscle
strength decline at different rates in elderly people</article-title>. <source>J Phys
Ther Sci</source>, <year>2014</year>, <volume>26</volume>:
<fpage>583</fpage>&#x02013;<lpage>586</lpage>. <pub-id pub-id-type="pmid">24764638</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Tsubaki</surname><given-names>A</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>: <article-title>Age-related changes in physical function in
community-dwelling people aged 50&#x02013;79 years</article-title>. <source>J Phys Ther
Sci</source>, <year>2010</year>, <volume>22</volume>:
<fpage>23</fpage>&#x02013;<lpage>27</lpage>. </mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Dias</surname><given-names>FM</given-names></name><name><surname>Costa</surname><given-names>SO</given-names></name><name><surname>Pereira de Freitas</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>: <article-title>Functional capacity of oldest old living in a long-stay
institution in Rio de Janeiro, Brazil</article-title>. <source>J Phys Ther Sci</source>,
<year>2014</year>, <volume>26</volume>: <fpage>1097</fpage>&#x02013;<lpage>1105</lpage>.
<pub-id pub-id-type="pmid">25140105</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Hyatt</surname><given-names>RH</given-names></name><name><surname>Whitelaw</surname><given-names>MN</given-names></name><name><surname>Bhat</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>: <article-title>Association of muscle strength with functional status of
elderly people</article-title>. <source>Age Ageing</source>, <year>1990</year>,
<volume>19</volume>: <fpage>330</fpage>&#x02013;<lpage>336</lpage>. <pub-id pub-id-type="pmid">2251967</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Montgomery</surname><given-names>HE</given-names></name><name><surname>Marshall</surname><given-names>R</given-names></name><name><surname>Hemingway</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>: <article-title>Human gene for physical performance</article-title>.
<source>Nature</source>, <year>1998</year>, <volume>393</volume>:
<fpage>221</fpage>&#x02013;<lpage>222</lpage>. <pub-id pub-id-type="pmid">9607758</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Alvarez</surname><given-names>R</given-names></name><name><surname>Terrados</surname><given-names>N</given-names></name><name><surname>Ortolano</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>: <article-title>Genetic variation in the renin-angiotensin system and
athletic performance</article-title>. <source>Eur J Appl Physiol</source>,
<year>2000</year>, <volume>82</volume>: <fpage>117</fpage>&#x02013;<lpage>120</lpage>.
<pub-id pub-id-type="pmid">10879452</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Folland</surname><given-names>J</given-names></name><name><surname>Leach</surname><given-names>B</given-names></name><name><surname>Little</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>: <article-title>Angiotensin-converting enzyme genotype affects the
response of human skeletal muscle to functional overload</article-title>. <source>Exp
Physiol</source>, <year>2000</year>, <volume>85</volume>:
<fpage>575</fpage>&#x02013;<lpage>579</lpage>. <pub-id pub-id-type="pmid">11038409</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Williams</surname><given-names>AG</given-names></name><name><surname>Rayson</surname><given-names>MP</given-names></name><name><surname>Jubb</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>The ACE gene and muscle performance</article-title>.
<source>Nature</source>, <year>2000</year>, <volume>403</volume>: <fpage>614</fpage>.
<pub-id pub-id-type="pmid">10688186</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Montgomery</surname><given-names>HE</given-names></name><name><surname>Clarkson</surname><given-names>P</given-names></name><name><surname>Dollery</surname><given-names>CM</given-names></name><etal>et al.</etal></person-group>: <article-title>Association of angiotensin-converting enzyme gene I/D
polymorphism with change in left ventricular mass in response to physical
training</article-title>. <source>Circulation</source>, <year>1997</year>,
<volume>96</volume>: <fpage>741</fpage>&#x02013;<lpage>747</lpage>. <pub-id pub-id-type="pmid">9264477</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Myerson</surname><given-names>S</given-names></name><name><surname>Hemingway</surname><given-names>H</given-names></name><name><surname>Budget</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>: <article-title>Human angiotensin I-converting enzyme gene and endurance
performance</article-title>. <source>J Appl Physiol 1985</source>, <year>1999</year>,
<volume>87</volume>: <fpage>1313</fpage>&#x02013;<lpage>1316</lpage>. <pub-id pub-id-type="pmid">10517757</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Puthucheary</surname><given-names>Z</given-names></name><name><surname>Skipworth</surname><given-names>JR</given-names></name><name><surname>Rawal</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>: <article-title>The ACE gene and human performance: 12 years
on</article-title>. <source>Sports Med</source>, <year>2011</year>, <volume>41</volume>:
<fpage>433</fpage>&#x02013;<lpage>448</lpage>. <pub-id pub-id-type="pmid">21615186</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Di Bari</surname><given-names>M</given-names></name><name><surname>Franse</surname><given-names>LV</given-names></name><name><surname>Kritchevsky</surname><given-names>SB</given-names></name><etal>et al.</etal></person-group>: <article-title>Cardiovascular medications and muscle wasting in older
adults</article-title>. <source>Circulation</source>, <year>2000</year>,
<volume>102</volume>: <fpage>842</fpage>&#x02013;<lpage>846</lpage>.</mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Sumukadas</surname><given-names>D</given-names></name><name><surname>Witham</surname><given-names>MD</given-names></name><name><surname>Struthers</surname><given-names>AD</given-names></name><etal>et al.</etal></person-group>: <article-title>Effect of perindopril on physical function in elderly
people with functional impairment: a randomized controlled trial</article-title>.
<source>CMAJ</source>, <year>2007</year>, <volume>177</volume>:
<fpage>867</fpage>&#x02013;<lpage>874</lpage>. <pub-id pub-id-type="pmid">17923654</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Mire</surname><given-names>DE</given-names></name><name><surname>Silfani</surname><given-names>TN</given-names></name><name><surname>Pugsley</surname><given-names>MK</given-names></name></person-group>: <article-title>A review of the structural and functional features of
olmesartan medoxomil, an angiotensin receptor blocker</article-title>. <source>J
Cardiovasc Pharmacol</source>, <year>2005</year>, <volume>46</volume>:
<fpage>585</fpage>&#x02013;<lpage>593</lpage>. <pub-id pub-id-type="pmid">16220064</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Vandenbroucke</surname><given-names>JP</given-names></name><name><surname>von Elm</surname><given-names>E</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><etal>et al.</etal></person-group>STROBE Initiative: <article-title>Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE): explanation and
elaboration</article-title>. <source>Epidemiology</source>, <year>2007</year>,
<volume>18</volume>: <fpage>805</fpage>&#x02013;<lpage>835</lpage>. <pub-id pub-id-type="pmid">18049195</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="other">WHO<year>2002</year>. Active
ageing. A policy framework. A contribution of the World Health Organization to the Second
United Nations World Assembly on Ageing.</mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="book">IBGE (Brazilian Institute of
Geography and Statistics): Demographic census, Brazil. <year>2010</year>.</mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Lutz</surname><given-names>W</given-names></name><name><surname>K C</surname><given-names>S</given-names></name></person-group>: <article-title>Dimensions of global population projections: what do we
know about future population trends and structures?</article-title><source>Philos Trans
R Soc Lond B Biol Sci</source>, <year>2010</year>, <volume>365</volume>:
<fpage>2779</fpage>&#x02013;<lpage>2791</lpage>. <pub-id pub-id-type="pmid">20713384</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal">ATS Committee on Proficiency
Standards for Clinical Pulmonary Function Laboratories: <article-title>ATS statement:
guidelines for the six-minute walk test</article-title>. <source>Am J Respir Crit Care
Med</source>, <year>2002</year>, <volume>166</volume>:
<fpage>111</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="pmid">12091180</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Troosters</surname><given-names>T</given-names></name><name><surname>Gosselink</surname><given-names>R</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name></person-group>: <article-title>Six minute walking distance in healthy elderly
subjects</article-title>. <source>Eur Respir J</source>, <year>1999</year>,
<volume>14</volume>: <fpage>270</fpage>&#x02013;<lpage>274</lpage>. <pub-id pub-id-type="pmid">10515400</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Vianna</surname><given-names>LC</given-names></name><name><surname>Oliveira</surname><given-names>RB</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>CG</given-names></name></person-group>: <article-title>Age-related decline in handgrip strength differs according
to gender</article-title>. <source>J Strength Cond Res</source>, <year>2007</year>,
<volume>21</volume>: <fpage>1310</fpage>&#x02013;<lpage>1314</lpage>. <pub-id pub-id-type="pmid">18076278</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Mathiowetz</surname><given-names>V</given-names></name><name><surname>Kashman</surname><given-names>N</given-names></name><name><surname>Volland</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>: <article-title>Grip and pinch strength: normative data for
adults</article-title>. <source>Arch Phys Med Rehabil</source>, <year>1985</year>,
<volume>66</volume>: <fpage>69</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="pmid">3970660</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Onder</surname><given-names>G</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Balkrishnan</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>: <article-title>Relation between use of angiotensin-converting enzyme
inhibitors and muscle strength and physical function in older women: an observational
study</article-title>. <source>Lancet</source>, <year>2002</year>, <volume>359</volume>:
<fpage>926</fpage>&#x02013;<lpage>930</lpage>. <pub-id pub-id-type="pmid">11918911</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Vescovo</surname><given-names>G</given-names></name><name><surname>Dalla Libera</surname><given-names>L</given-names></name><name><surname>Serafini</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>: <article-title>Improved exercise tolerance after losartan and enalapril
in heart failure: correlation with changes in skeletal muscle myosin heavy chain
composition</article-title>. <source>Circulation</source>, <year>1998</year>,
<volume>98</volume>: <fpage>1742</fpage>&#x02013;<lpage>1749</lpage>. <pub-id pub-id-type="pmid">9788828</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Corder</surname><given-names>CN</given-names></name><name><surname>Rubler</surname><given-names>S</given-names></name><name><surname>Deere</surname><given-names>LF</given-names></name><etal>et al.</etal></person-group>: <article-title>Effect of cilazapril on exercise tolerance in congestive
heart failure</article-title>. <source>Pharmacology</source>, <year>1993</year>,
<volume>46</volume>: <fpage>148</fpage>&#x02013;<lpage>154</lpage>. <pub-id pub-id-type="pmid">8441761</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Schaufelberger</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>G</given-names></name><name><surname>Eriksson</surname><given-names>BO</given-names></name><etal>et al.</etal></person-group>: <article-title>Skeletal muscle changes in patients with chronic heart
failure before and after treatment with enalapril</article-title>. <source>Eur Heart
J</source>, <year>1996</year>, <volume>17</volume>:
<fpage>1678</fpage>&#x02013;<lpage>1685</lpage>. <pub-id pub-id-type="pmid">8922916</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group><name><surname>Henriksen</surname><given-names>EJ</given-names></name><name><surname>Jacob</surname><given-names>S</given-names></name><name><surname>Kinnick</surname><given-names>TR</given-names></name><etal>et al.</etal></person-group>: <article-title>ACE inhibition and glucose transport in insulinresistant
muscle: roles of bradykinin and nitric oxide</article-title>. <source>Am J
Physiol</source>, <year>1999</year>, <volume>277</volume>:
<fpage>R332</fpage>&#x02013;<lpage>R336</lpage>. <pub-id pub-id-type="pmid">10409290</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group><name><surname>Hespel</surname><given-names>P</given-names></name><name><surname>Vergauwen</surname><given-names>L</given-names></name><name><surname>Vandenberghe</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>: <article-title>Significance of insulin for glucose metabolism in skeletal
muscle during contractions</article-title>. <source>Diabetes</source>,
<year>1996</year>, <volume>45</volume>: <fpage>S99</fpage>&#x02013;<lpage>S104</lpage>.
<pub-id pub-id-type="pmid">8529809</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group><name><surname>Kranzh&#x000f6;fer</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>J</given-names></name><name><surname>Pfeiffer</surname><given-names>CA</given-names></name><etal>et al.</etal></person-group>: <article-title>Angiotensin induces inflammatory activation of human
vascular smooth muscle cells</article-title>. <source>Arterioscler Thromb Vasc
Biol</source>, <year>1999</year>, <volume>19</volume>:
<fpage>1623</fpage>&#x02013;<lpage>1629</lpage>. <pub-id pub-id-type="pmid">10397679</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Peng</surname><given-names>HB</given-names></name><etal>et al.</etal></person-group>: <article-title>Nitric oxide decreases cytokine-induced endothelial
activation. Nitric oxide selectively reduces endothelial expression of adhesion
molecules and proinflammatory cytokines</article-title>. <source>J Clin Invest</source>,
<year>1995</year>, <volume>96</volume>: <fpage>60</fpage>&#x02013;<lpage>68</lpage>.
<pub-id pub-id-type="pmid">7542286</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group><name><surname>Vanhoutte</surname><given-names>PM</given-names></name></person-group>: <article-title>Endothelium-dependent responses and inhibition of
angiotensin-converting enzyme</article-title>. <source>Clin Exp Pharmacol
Physiol</source>, <year>1996</year>, <volume>23</volume>:
<fpage>S23</fpage>&#x02013;<lpage>S29</lpage>. <pub-id pub-id-type="pmid">8886509</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group><name><surname>Schieffer</surname><given-names>B</given-names></name><name><surname>Wollert</surname><given-names>KC</given-names></name><name><surname>Berchtold</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>Development and prevention of skeletal muscle structural
alterations after experimental myocardial infarction</article-title>. <source>Am J
Physiol</source>, <year>1995</year>, <volume>269</volume>:
<fpage>H1507</fpage>&#x02013;<lpage>H1513</lpage>. <pub-id pub-id-type="pmid">7503242</pub-id></mixed-citation></ref></ref-list></back></article>